MET and non-small cell lung carcinoma: Tepotinib was also combined with gefitinib for NSCLC and showed superiority compared to standard-of-care chemotherapy.800 In case of lorlatinib (ROS1/ALK-inhibitor) resistance, combination with a pan-HER2-inhibitor (afatinib or dacomitinib) seems to overcome resistance in vitro in NSCLC cells.801 Resistance to ROS-1 inhibitor entrectinib may be overcome by adding a MET-inhibitor.760 Doublets of third- and fourth-generation EGFR-inhibitors are also studied.